India Patent Case Threatens Cheap Drug Supply: Doctors Without Borders
September 6, 2011
Doctors Without Borders (DWB) warned Monday that a challenge to India's patent law could interrupt the global supply of low-cost generic drugs.
Novartis is contesting the Indian patent office's rejection of an application for an updated version of its leukemia drug Glivec. Indian law stipulates that patents cannot be issued for older drugs unless changes make them significantly more therapeutically effective. DWB called the updated version of Glivec a "minor modification." India's Supreme Court on Tuesday will hear an appeal by Novartis on Glivec's status.
Agence France Presse
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)